DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Low-dose Gonal-f® in Ovulation Induction

Information source: Merck KGaA
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Infertility; Monofollicular Development

Intervention: Gonal-f® (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Merck KGaA

Official(s) and/or principal investigator(s):
Medical Responsible, Study Director, Affiliation: Merck Serono Limited, UK


This is a prospective, multicenter, open-label, comparative and parallel-group study of ovulation induction evaluating tailoring of Recombinant follicle stimulating hormone (FSH) treatment using the Gonal-f prefilled pen in World Health Organization (WHO) Type 2 anovulatory subjects who have previously failed to conceive with clomifene treatment.

Clinical Details

Official title: A Multi-Centre, Two-Arm, Interventional, Phase IV Study to Evaluate Tailoring of Recombinant FSH Treatment in Subjects With Chronic Anovulation Using the Gonal-f Prefilled Pen in Women Undergoing Ovulation Induction

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Percentage of cycles with monofollicular development that is, only one follicle greater than or equal to 17 millimeter and no other follicles greater than or equal to 14 millimeter

Secondary outcome:

Percentage of cycles with bifollicular development that is, only two follicles greater than or equal to 17 millimeter

Percentage of cycles with multifollicular development that is, three or more follicles greater than or equal to 14 millimeter

Percentage of ovulatory cycles

Percentage of cycles wherein hCG was not administered

Percentage of cycles resulting in clinical pregnancy

Number of multiple pregnancy

Number of fetuses

Number of miscarriages after confirmation of clinical pregnancy

Number of subjects with Ovarian Hyper Stimulation Syndrome (OHSS)

Duration of Recombinant Follicle Stimulating Hormone (rFSH) stimulation

Total Dose of Recombinant Follicle Stimulating Hormone (r-FSH) administered per cycle

Change from Baseline in Anti-Mullerian Hormone (AMH) levels at Week 4

Testosterone levels

Sex Hormone Binding Globulin (SHBG) levels

Detailed description: Subjects will enter a screening period of up to one month before being randomized at the Baseline Visit, which will occur on Day 1 of the subject's menstrual cycle. Each subject will then receive up to 4 weeks treatment with Gonal-f®. If adequate follicular development (assessed by transvaginal ultrasound) is achieved, the subject will proceed to administration of human chorionic gonadotropin (hCG) within 24-48hrs of last Gonal-f® injection (or according to standard site practice). Following administration of hCG, subjects will attempt to become pregnant via intercourse or intrauterine insemination. The method of conception will be determined by the subject's requirements and standard practice at the clinic site. All subjects will be followed up appropriately until confirmation of biochemical pregnancy (hCG + minimum 14 days) and clinical pregnancy (hCG + minimum 42 days, for subjects with positive biochemical pregnancy test).


Minimum age: 18 Years. Maximum age: 37 Years. Gender(s): Female.


Inclusion Criteria:

- Subjects eligible for ovulation induction treatment, where monofollicular development

is the desired treatment outcome and the dose schedule outlined in the protocol is deemed appropriate

- Premenopausal female subjects, aged between 18 and 37 years inclusive

- Subjects desirous of pregnancy/willing to conceive

- Subjects who are infertile due to chronic anovulation demonstrated by cycle duration

of greater than 35 days.

- Subjects who have been treated with clomifene citrate therapy, according to standard

site practice, and have failed to ovulate and/or conceive

- Subjects with follicle stimulating hormone (FSH) and prolactin (PRL) serum values

within the normal range in the early follicular phase

- Subjects with an overall total antral follicle count greater than 10 (of follicle

size greater than or equal to 2 millimeter [mm] and less than 11 mm) (that is, total between both ovaries)

- Subjects with at least one patent tube, as documented by recent (within 2 years

before treatment assignment) hysterosalpingography (HSG) or hysterosalpingo contrast sonography (HyCoSy)

- Subjects with normal uterine cavity, as documented by recent (within 2

years before treatment assignment) hysteroscopy, HSG or ultrasound scan

- Subjects with body mass index (BMI) greater than 20 and less than or equal to

32 kilogram per square meter (kg/m^2) (BMI is equal to body weight [kilogram {kg}] divided by Height * Height [square meter {m^2}])

- Subjects with negative cervical Papanicolaou (PAP) test conducted according to

national guidelines and/or standard site practice

- Male partners of female subjects with sperm compatible with non-assisted

fertilization or availability of donor sperm, as confirmed by the Investigator

- Subjects who are willing and able to comply with protocol requirements and have

provided written, informed consent Exclusion Criteria:

- Subjects with history of hypersensitivity to the investigational medicinal product

(IMP) (active substance follitropin alpha, FSH, or to any of the excipients of Gonal-f®) or any other drug used in the trial (that is, Ovitrelle)

- Subjects with ovarian enlargement or ovarian cyst unrelated to Polycystic Ovary

Syndrome (PCOS), and of unknown origin on ultrasound

- Subjects with evidence of diminished ovarian reserve (cycle length less than 26 days;

FSH above the upper limit of local serum FSH values, total antral follicle count [AFC] in both ovaries less than 10)

- Subjects with uterine pathology/abnormalities, which in the opinion of the

Investigator could impair pregnancy evolution

- Subjects who have undergone three or more previous miscarriages

- Subjects with any previous extrauterine pregnancy

- Pregnant or lactating female subjects

- Subjects with abnormal gynecological bleeding of unknown etiology.

- Subjects with previous history of severe ovarian hyper stimulation syndrome

(OHSS) (after clomifene treatment)

- Subjects who have evidence of current or previous pelvic inflammatory disease

before treatment assignment

- Subjects with tumors of the hypothalamus and pituitary gland

- Subjects with ovarian, uterine or mammary carcinoma

- Subjects treated with clomifene citrate or gonadotropins within 1 month of the

screening evaluation

- Subjects with any medical condition which, in the opinion of the Investigator,

would prevent an effective response, such as primary ovarian failure, or malformations of the reproductive organs incompatible with pregnancy

- Subjects with any medical condition which, in the opinion of the Investigator, may

interfere with the absorption, distribution, metabolism or excretion of the drug

- Subjects with any clinically significant systemic disease (for example,

insulin-dependent diabetes) or any contraindication to being pregnant and/or carrying a pregnancy to term

- An active substance abuser

- Known infection with human immunodeficiency virus (HIV), Hepatitis B or C virus

in the trial subject or her male partner

- Subjects who are currently participating in another clinical trial

- Subjects who are unable to give written informed consent

Locations and Contacts

Research Site, Cork, Ireland

Research Site, Galway, Ireland

Research Site, Cambridge, United Kingdom

Research site, Cheshunt, United Kingdom

Research Site, Derby, United Kingdom

Research Site, Edinburgh, United Kingdom

Research Site, Glasgow, United Kingdom

Research site, London, United Kingdom

Additional Information

Starting date: July 2013
Last updated: February 18, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017